BetterLife/Altum Merger ‘Triggered By Early COVID-19 Promise’

BetterLife’s CEO Explains Altum Acquisition Logic

Created when BetterLife bought Altum at end-July, the merged entity will now focus on advancing the acquired group’s lead asset, an inhaled form of its patented interferon a2b product, as an early treatment for COVID-19.    

Jigsaw
Merged group will focus on an inhaled interferon-based therapy for Covid-19 • Source: Shutterstock

Rising evidence that interferons could be used as potential treatments for COVID-19 led last month to Canada-based BetterLife Pharma Inc. acquiring Altum Pharmaceuticals Inc., giving it ownership of a small pipeline of therapeutics that includes AP-003, an inhaled interferon-based therapy that will now enter Phase II testing as an early treatment for the disease.

Momentum for the merger came from recent studies in China and the UK suggesting the therapeutic efficacy of interferon-based treatments...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.